other·preclinical research, biomedical research, neurology, obstetrics and gynecology·PMC10455234
Developmental Toxicity Study of DL-4-Hydroxy-4-Phenylhexanamide (DL-HEPB) in Rats
Life · 6 authors, 3 centres
AI SUMMARY
FIDELITY 100%
POPULATIONPregnant Wistar rats
INTERVENTIONOral administration of DL-4-hydroxy-4-phenylhexanamide (DL-HEPB)
COMPARISONControl group (0 mg/kg)
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
It found no developmental toxicity at doses up to 100 mg/kg, but a dose of 200 mg/kg caused low-frequency malformations in the brain and kidneys of fetuses.
Full summary
693 CHARS
This preclinical study evaluated the developmental toxicity of the novel anticonvulsant DL-HEPB in pregnant Wistar rats. Maternal observations included decreased food consumption and weight gain at the highest dose. Fetal examination on gestation day 21 revealed no external, visceral, or skeletal malformations at doses up to 100 mg/kg. However, the 200 mg/kg dose resulted in a significant increase in fetal resorptions and a low frequency of hydrocephalus and hydronephrosis. The study concludes that DL-HEPB is developmentally safe at doses ≤100 mg/kg but may be teratogenic at 200 mg/kg. Limitations include the use of a single animal species and the need for further mechanistic studies.
PICO
PPOPULATION
Pregnant Wistar rats
IINTERVENTION
Oral administration of DL-4-hydroxy-4-phenylhexanamide (DL-HEPB)
OOUTCOME
External, visceral, and skeletal malformations in fetuses; maternal food consumption and weight gain
